关于治疗心脏衰竭的心房转移疗法的最新情况
Sheldon E Litwin1,2, Barry A Borlaug3, Jan Komtebedde4
1Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Structural heart : the journal of the Heart Team
|June 8, 2023
概括
在心力衰竭中,心房间际冲刺 (IAS) 可能会降低左心房压力,并保留排气分数. 虽然安全,但该设备并没有使整体人口受益,但在特定的患者亚组中显示出有前途.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭研究研究
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭涉及运动期间左心房压力升高.
- 目前的治疗方法,包括SGLT2抑制剂,提供了适度的改善,需要新的方法.
- 降低运动左心房压力的非药理方法具有显著的兴趣.
研究的目的:
- 审查目前关于HFpEF的耳间分流 (IAS) 治疗的证据.
- 总结最近对IAS设备进行的随机对照试验的发现.
- 为了确定潜在的响应者和不响应者群体用于IAS治疗.
主要方法:
- 对HFpEF的耳间分流装置的已公布数据的审查.
- 对第一个大规模随机对照试验的结果进行分析.
- 检查预规定的和后期的小组分析.
主要成果:
- 植入IAS设备是安全的,并没有增加中风发病率.
- 整体人群没有证明IAS治疗具有显著的临床益处.
- 亚组分析表明,在患有较低肺血管阻力和没有心脏起器的患者中,潜在的益处.
结论:
- 腹腔间的分流疗法是HFpEF的一种安全的研究方法.
- 患者的选择至关重要,因为好处在HFpEF人群中并不普遍.
- 需要进一步的研究来确定最佳的患者形状,并完善IAS设备治疗.
相关概念视频
Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
Mitral Stenosis III: Medical Management
14
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
14
Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18
Mitral Regurgitation III: Medical Management
20
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
20
Aortic Regurgitation III: Medical Management
26
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
26
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16


